Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Consortium on Organ Preservation in Europe (COPE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Netherlands,Germany,Germany,France,France,Belgium,Spain,France,Spain,United Kingdom,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2018-06-30
Duration (months): 66.0
Total project cost (EUR): 7847753.15
EU funding (EUR): 5990843.0
Participants: 15
Project status: CLOSED

The discrepancy between organ supply and demand remains the biggest challenge facing the transplant community today. In order to increase the amount of available donor organs, transplant specialists are increasingly turning to sub-optimal donor organs. Organs from such donors, usually have normal or near normal function before death, but retrieval, storage and transplantation cause progressive injury to the organ. Injury is predominantly caused by inadequate or absent delivery of oxygen and nutrients, either in the warm or cold preservation environment. New techniques to improve organ preservation are being developed and the COPE consortium including: • Normothermic liver machine perfusion (NMP) • Hypothermic kidney machine perfusion (HMP) • Novel additives for preservation solutions These strategies are all directed to the vital period that starts at the time of circulatory arrest and extends to the point of transplantation. Specifically, they will tackle the following challenges: • Exposure of donor organs to ischaemic injury whilst the organs remain in the donor. • Progressive deterioration of the organ during conventional organ preservation. • Repair of the organ during preservation using perfusate and pharmacological interventions. • Identification of reliable predictors of organ viability using biological and other pre-transplant parameters. The COPE consortium is the official organ preservation task force of ESOT and consists of a number of European transplantation centers, front running transplantation research groups and a number of SMEs involved in developing perfusion fluids and technology. Together, they will be able to generate the statistical power and protocols necessary to test, validate and promote these new organ preservation techniques and increase the number of available solid donor organs.

Keywords: organ,transplants
Emerging mental health systems in low- and middle-income countries (EMERALD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Spain,Switzerland,Ethiopia,India,Nigeria,South Africa,Uganda,Germany,Nepal,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2017-10-31
Duration (months): 60.0
Total project cost (EUR): 7255185.59
EU funding (EUR): 5798173.0
Participants: 13
Project status: CLOSED

The objective of the EMERALD Project is to improve mental health outcomes by enhancing health system performance. The key issues addressed are: (i) adequate, fair & sustainable resourcing: using human, infrastructural, informational & financial resource inputs to effectively deliver better mental health services; (ii) integrated service provision: enhancing access to integrated community care; and (iii) improved coverage & goal attainment: scaled-up, appropriate and cost-effective care in the community & reduction of disease burden & economic impacts. We are innovative in: (i) our track record to work collaboratively across health system boundaries; (ii) excellent ability to deliver on agreed work packages; (iii) delivering high quality & precisely relevant capacity development materials to our key target groups; & (iv) key leadership roles eg in developing the WHO mhGAP Implementation Guide. We are committed to taking the health system strengthening steps necessary for its realization in Ethiopia, India, Nepal, Nigeria, South Africa & Uganda.

Keywords: mental health,health systems,health service,low and middle income countries,scaling up,healthcare policy.
Advancing and strengthening the methodological tools and practices relating to the application and implementation of Health Technology Assessment (HTA) (ADVANCE_HTA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: United Kingdom,Italy,Spain,Slovenia,Germany,Spain,United States,Belgium,France,Poland,Sweden
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2015-12-31
Duration (months): 36.0
Total project cost (EUR): 4035099.15
EU funding (EUR): 2999805.0
Participants: 13
Project status: CLOSED

The use of HTA has increased recently in Europe and more widely (e.g. Americas) to enable evidence-based coverage decisions and improve efficiency in resource allocation. HTA has often resulted in different coverage decisions across settings despite the same evidence being used for this purpose. This may reflect in part societal preferences about value, priorities or risk perceptions, suggesting a significant need for methodological improvements and extensions. The fundamental objective of ADVANCE_HTA is to contribute to advancements in the methods for HTA in European and other settings by involving the wider stakeholder community in areas actively and heavily debated given their implications for decision-making and resource allocation, as follows: • First, the issue around value for money and the different approaches surrounding current thresholds for resource allocation; • Second, the concept of value assessment, and the factors that need to be considered beyond cost effectiveness, such as disease severity; • Third, to improve the quality of the evidence required for and the methods associated with the assessment of rare diseases; • Fourth, to advance the debate in the elicitation of preferences by deriving these in more realistic settings within the patient community in the wider EU; • Fifth, to advance the debate on the suitability of current HTA tools across different categories of medical devices (e.g. diagnostics); and • Sixth, to improve the implementation and capacity building of HTA including outside Europe, where HTA is considered explicitly in decision-making. ADVANCE_HTA aims to broaden the spectrum, complement and address areas of intense methodological debate in the application, use and implementation of HTA. It also aims to improve HTA methods, which can be taken further by competent authorities nationally whilst supplementing the work of supra-national bodies (e.g. EUnetHTA) towards a common understanding of choices in health care decision-making.

Keywords: health technology assessment,rare disease,medical devices,value for money,burden of disease,disease severity,capacity building of hta,value assessment,efficiency in resource allocation
King of hearts, joints and lungs; periodontal pathogens as etiologic factor in RA, CVD and COPD and their impact on treatment strategies. (TRIGGER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Norway,Poland,Denmark,Spain,Spain,Germany,Sweden,Israel,United Kingdom,Switzerland
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-04-01
End date: 2017-03-31
Duration (months): 48.0
Total project cost (EUR): 7837584.53
EU funding (EUR): 5982363.0
Participants: 11
Project status: CLOSED

Extensive clinical and epidemiological data clearly shows that chronic periodontal disease (PD), the most prevalent infectious inflammatory disease of mankind, is strongly linked to systemic inflammatory diseases such as cardiovascular diseases (CVD) , rheumatoid arthritis (RA) , and chronic obstructive pulmonary disease (COPD) . Taking into account that up to 30% of the adult population worldwide suffers from severe periodontitis , the impact of this disease on human health is immense and has been recognized by World Health Organization . Nevertheless, in many EU countries PD is a neglected disease, both by the population in general and health-care personnel. Often this negligence comes to the point that, like a hair-loss, the tooth-loss due to periodontitis is still considered as a normal inevitable event associated with aging. To combat this misconception and conceive novel approaches to prevent and/or treat CVD, RA, and COPD we will explore highly innovative ideas that these non-communicable diseases are at least aggravated, if not initiated, by periodontal infection. Results emanating from our project will: i) elucidate a relationship between the presence of specific periodontal pathogens and severity of systemic diseases; ii) show that extensive periodontal treatment improves clinical parameters of investigated systemic diseases; iii) reveal the impact of eradication of specific periodontal pathogen on the level of inflammatory markers; iv) develop novel, periodontal-pathogen specific bactericidal compounds based on periodontal glutaminyl cyclase (QC), the enzyme essential for these pathogens vitality. This will reduce mortality and ameliorated quality of life of CVD, RA, and COPD patients. All of these will be possible based on the knowledge of mechanisms beyond the causative links between specific pathogen driven periodontal disease and CVD, RA, and COPD revealed by research program outlined in this project.

Keywords: copd,cvd,atherosclerosis,p.gingivalis,periodontitis,systemic diseases,post-translational modifications,inflammation
Engaging Game-based Home Rehabilitation for Improved Quality of Life (REHAB@HOME)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Germany,Italy,Italy,Austria,Israel,Austria
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2015-09-30
Duration (months): 36.0
Total project cost (EUR): 3192067.68
EU funding (EUR): 2367042.67
Participants: 9
Project status: CLOSED

The proposed REHAB4LIFE project is intended as an advanced activity – with the involvement of highly qualified medical and technical partners, as well as real patients - aimed at an extensive investigation of the issues related to long-term physical/cognitive rehabilitation processes and the identification of suitable technical solutions to efficiently support them. REHAB4LIFE will enable elderly people to enjoy high quality rehabilitation for a much longer period than the Health System can currently afford. By investigating and using standard hardware components and devices, suitable medical data processing algorithms, personalized and serious-games based rehabilitation pathways, Web2.0 social and communication tools, the project will develop an efficient, effective and engaging virtual rehabilitation environment for home-based rehabilitation. The basic project idea is inspired by existing commercial platforms, like Wii and Kinect, that allow the user acting within a virtual environment and interacting with other users, thanks to special input devices and suitable technologies able to monitor the real environment and track the user’s behavior. Having this in mind, REHAB4LIFE aim at the user-centred design and development of an open solution capable to: provide exercises and training - based on serious-games - within a personalized, user friendly and engaging rehabilitation program, offer a cost effective and not bulky infrastructure with sensors integrated, collect relevant physical and medical parameters for patients’ status inspection and relapse prevention, support off-line/on-line management and monitoring of the rehabilitation protocol, promote patient’s social participation and community building. In other words, REHAB4LIFE will transform the patient’s home in a place where physical and cognitive rehabilitation process can be performed in an intensive and engaging though properly controlled way, while promoting social inclusion and quality of life.

Keywords: home-based rehabilitation,serious games,monitoring,social inclusion,active ageing,engagement
WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients. (WINTHER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: France,United States,Spain,Israel,France,Canada,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-03-01
End date: 2015-02-28
Duration (months): 24.0
Total project cost (EUR): 4229837.02
EU funding (EUR): 2998355.0
Participants: 11
Project status: CLOSED

Relevance: WINTHER project focuses on the development and validation, in 24 months, of industry supported new tools and computational methods, to predict efficacy of drugs in cancer patients Current medical needs: Selection of cancer targeted therapies based on molecular abnormalities (mutations /amplifications/ translocations) benefit today only to 10-40% of patients. For the remaining majority, therapeutic decision is still based according to decade-old protocols with limited efficacy. Drug development depends on efficiency of clinical trials, with a staggering 95% failure rate The objective: WINTHER proposes a fundamental change in trial design, through: 1. investigation of the tumour simultaneously with the normal matched tissue 2. development of a comprehensive database and genomic based algorithms and computational tools to predict the efficacy of drugs at individual level, in all patients, irrespective of cancer type 3. increase efficacy of therapeutics and clinical outcome, Impact: Optimization of the portfolio of existing drugs and new compounds in clinical trials by matching the right drug to the right patient. In particular, it permits to avoid use of expensive drugs for patients that would not benefit from such treatments. WINTHER will made available to community as a clinically validated industry tool (website, database and algorithms) to assist clinicians in the analysis of genomic information based on the comparison of tumour and matched normal tissue and to increase the number of the patients to benefit from individualized rational selection of therapies.

Keywords: predict efficacy,cancer therapeutics,clinical trials,biomarkers
Enhancing and Tuning Electroluminescence with Nanoantennas (EN-LUMINATE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Physical and Analytical Chemical sciences
Countries involved: Germany,Germany
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2012-12-01
End date: 2017-11-30
Duration (months): 60.0
Total project cost (EUR): 1496684.0
EU funding (EUR): 1496684.0
Participants: 2
Project status: CLOSED

Being able to enhance and tune the interaction of a light wave with a molecule or nanoparticle on a fundamental level opens up an exciting range of applications such as more efficient solar cells, more sensitive photon detectors and brighter emitters for lighting applications. Nanoplasmonics promises to offer this level of control. Taking the current knowledge on nanoantennas a step further we will integrate them in organic and carbon-nanotube light-emitting devices to improve and tune their emission in unprecedented ways. As our testing platform we will use light-emitting field-effect transistors (LEFETs). Their planar structure, where the light emission zone can be positioned at any point allows for easy and controlled incorporation of plasmonic structures without interfering with charge transport. LEFETs can be made from a wide range of semiconducting materials. We will apply nanoantennas in LEFETs to 1) Enhance electroluminescence of high mobility organic semiconductors 2) Tune excitation decay and transition selection rules in organic semiconductors and 3) Enhance photo- and electroluminescence of single-walled carbon nanotubes. All of these materials offer high carrier mobilities and therefore high currents but have very low fluorescence efficiencies that can be improved substantially by nanoantennas. We will study the influence of nanoantennas on the fundamental emission properties of these different types of emitters. At the same time we will improve their efficiency in light-emitting devices and thus enable new and innovative applications.

Keywords: light-emission,electroluminescence,fluorescence,nanoplasmonics,nanoantennas,charge transport,organic semiconductors,carbon nanotubes
Probing General Relativity with Stellar Orbits (PROGRESO)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Universe sciences
Countries involved: Germany
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2013-04-01
End date: 2018-12-31
Duration (months): 69.0
Total project cost (EUR): 1187700.0
EU funding (EUR): 1187700.0
Participants: 1
Project status: CLOSED

Of the four fundamental forces in nature, gravity is the least tested one. A uniquely accessible laboratory for gravitational physics is the Galactic Center, hosting the closest massive black hole with 4 million solar masses. Its vicinity and the advent of high-resolution, near-infrared techniques allowed for the observation of ≈ 30 individual stellar orbits in its gravitational field. The stars are ideal test particles for the potential in which they move, and thus the keys to directly probing the gravitational potential are ultra-precise astrometry and radial velocities of the stars. All data to date can be described by Keplerian orbits around a single central mass. However, relativistic effects will lead to post-Newtonian orbits. These effects will soon be detectable with near-infrared interferometry for faint objects. With the next-generation instrument GRAVITY for the Very Large Telescope Interferometer of ESO the achievable resolution is ≈ 4 mas, and the astrometric accuracy ≈ 10 µas - the scale of the event horizon. This is an improvement of a factor ≈ 20 compared to current, adaptive-optics based data. PROGRESO aims at detecting the relativistic effects in the stellar orbits around Sgr A*. Also, the emission from hot spots close to the last stable orbit might be used. Scientifically, this will test gravity in a so far unprobed regime of mass and space-time curvature. The spin of the black hole might be determined in this way, and in the most optimistic case test the 'no-hair' theorem. With PROGRESO I would like to start a research group that focuses on interpreting the novel interferometric data of the Galactic Center with yet to be determined instrumental systematics, on exploiting it scientifically and on optimally combining it with existing and future data of the present instruments. The proposed research group will be hosted at MPE (Garching, Germany), the PI institute for GRAVITY, and therefore have access to commissioning and guaranteed time data.

Keywords: galactic center,massive black hole,stellar orbits,precison astrometry
Simulation of the Kinetics and Inverse Problem for the Protein PolymERization in Amyloid Diseases (Prion, Alzheimer’s) (SKIPPERAD)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Mathematical foundations
Countries involved: France,France
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2012-12-01
End date: 2018-07-31
Duration (months): 68.0
Total project cost (EUR): 1203569.0
EU funding (EUR): 1203569.0
Participants: 3
Project status: CLOSED

Amyloid diseases are of increasing concern in our aging society. These diseases all involve the aggregation of misfolded proteins, called amyloid, which are specific for each disease (PrP for Prion, Abeta for Alzheimer's). When misfolded these proteins propagate the abnormal configuration and aggregate to others, forming very long polymers also called fibrils. Elucidating the intrinsic mechanisms of these chain reactions is a major challenge of molecular biology: do polymers break or coalesce? Do specific sizes polymerize faster? What is the size of the so-called nucleus, i.e., the minimum stable size for polymers? On which part of the reactions should a treatment focus to arrest the disease ? Up to now, only very partial and partially justified answers have been provided. This is mainly due to the extremely high complexity of the considered processes, which may possibly involve an infinite number of species and reactions (and thus, an infinite system of equations). The great challenge of this project is to design new mathematical methods in order to model fibril reactions, analyse experimental data, help the biologists to discover the key mechanisms of polymerization in these diseases, predict the effects of new therapies. Our approach is based on a new mathematical model which consists in the nonlinear coupling of a size-structured Partial Differential Equation (PDE) of fragmentation-coalescence type, with a small number of Ordinary Differential Equations. On the one hand, we shall solve new and broad mathematical issues, in the fields of PDE analysis, numerical analysis and statistics. These problems are mathematically challenging and have a wide field of applications. On the other hand we want to test their efficacy on real data, thanks to an already well-established collaboration with a team of biophysicists. With such a continuing comparison with experiments, we aim at constantly aligning our mathematical problems to biological concerns.

Keywords: application of mathematics in biology,inverse problems,statistics,aggregation-fragmentation equation,structured population equations,prion model,biophysical chemistry